Angels Santé is proud to once again participate in Kimialys’ fundraising round, a company we have been following and supporting since 2022
Kimialys has announced a €3.6M Series A round, a major milestone to accelerate its commercial deployment and scale up to industrial production.
Founded in 2020 by Cyril GILBERT and Claude Nogues, Kimialys develops a breakthrough technology platform based on its patented K-One technology 👉 A key innovation that significantly improves the sensitivity, reliability and reproducibility of diagnostic tests and drug discovery assays, through precise surface functionalization of nanoparticles, biochips and electrodes.
This funding will enable:
– completion of the industrialization phase,
– scaling up production capacities,
– launch of ready-to-use kits,
– and acceleration of international commercial development.
At Angels Santé, with the help of Nicolas Felix, member and deal lead for the startup, we are delighted to continue supporting Kimialys over the long term and to accompany the team in this new phase of growth.
Congratulations to the founders, the team and all the investors involved!
🔗 www.kimialys.com
For more information, please see the press release below 👇